Zynerba Pharmaceuticals Company Profile (NASDAQ:ZYNE)

Zynerba Pharmaceuticals trades on the NASDAQ under the ticker symbol "ZYNE."

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced its quarterly earnings data on Tuesday, August, 1st. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.04. View Zynerba Pharmaceuticals' Earnings History.

9 analysts have issued 1 year target prices for Zynerba Pharmaceuticals' shares. Their predictions range from $7.00 to $32.00. On average, they anticipate Zynerba Pharmaceuticals' share price to reach $14.63 in the next twelve months. View Analyst Ratings for Zynerba Pharmaceuticals.

Here are some recent quotes from research analysts about Zynerba Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal cannabinoid therapeutics for indications including refractory epilepsy, Fragile X syndrome, osteoarthritis, fibromyalgia and peripheral neuropathic pain. Zynerba Pharmaceuticals, Inc. is headquartered in Devon, Pennsylvania. " (10/18/2017)
• 2. Cantor Fitzgerald analysts commented, "Encouraging, but Early. In our view, the effect sizes and statistical significant have been strongly encouraging for the small and exploratory Phase 2 study. Achieving 46% reduction (p<0.0001) across the primary endpoint of Anxiety, Depression, and Mood Scale (ADAMS), ZYN002 also has demonstrated clinically meaningful activity across domains of the disease as measured by Aberrant Behavior Checklist – FXS (ABC-FXS)."" (9/28/2017)
• 3. Maxim Group analysts commented, "Zynerba announced the completion of target pediatric patient enrollment (n=16, ages from 6 – 17 years old) in the Phase II FAB-C (Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) study to evaluate ZYN002, Zynerba’s cannabidiol (CBD) gel in children with Fragile X syndrome (FXS)." (6/8/2017)

Some companies that are related to Zynerba Pharmaceuticals include Horizon Discovery Group PLC (HZD), Nabriva Therapeutics AG (NBRV), Compugen (CGEN), Chromadex Corp (CDXC), Pluristem Therapeutics (PSTI), Merrimack Pharmaceuticals (MACK), Organovo Holdings (ONVO), Silence Therapeutics plc (SLN), Advaxis (ADXS), CASI Pharmaceuticals (CASI), Organovo Holdings (ONVO), Palatin Technologies (PTN), OncoMed Pharmaceuticals (OMED), Oramed Pharmaceuticals (ORMP), CTI BioPharma Corp. (CTIC), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST) and Regulus Therapeutics (RGLS).

Zynerba Pharmaceuticals' management team includes the folowing people:

• Armando Anido, Chairman of the Board, Chief Executive Officer
• Terri B. Sebree, President
• James E. Fickenscher, Chief Financial Officer, Vice President - Corporate Development
• Suzanne M. Hanlon, Secretary, General Counsel and Vice President, Human Resources
• William Roberts, Vice President - Investor Relations and Corporate Communications
• Ray Mannion, Vice President - Manufacturing
• Brian Rosenberger, Vice President - Commercial
• Warren D. Cooper M.D., Lead Independent Director
• William J. Federici, Independent Director
• Thomas L. Harrison, Independent Director

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at a price of $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Shares of Zynerba Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zynerba Pharmaceuticals stock can currently be purchased for approximately $9.73.